Immunome Inc.

IMNM

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Driehaus Capital Redmile Group Rock Springs Capital

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 3,705,974Value: $79.6M

# Signal Note: Driehaus Capital Initiates $79.6M Position in Immunome Driehaus' entry into IMNM (3.7M shares) signals conviction in Immunome's platform for discovering disease-fighting antibodies from long-lived plasma cells in chronic infection survivors. The timing likely reflects upcoming clinical or partnership milestones, though recent catalysts and pipeline stage warrant verification. Given Driehaus' selective biotech allocation, this suggests meaningful probability-adjusted value in IMNM's lead programs or M&A potential.

Redmile GroupNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NGNE4 funds NUVB3 funds BBIO3 funds XENE3 funds MBX3 funds SRRK3 funds GPCR3 funds NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Redmile Initiates $122.8M Position in Immunome Redmile's substantial entry into IMNM signals confidence in the company's B-cell characterization platform and clinical pipeline, particularly IMM-1-104 for autoimmune disease. The $122.8M stake (representing a meaningful position) from a sector-focused operator suggests conviction around near-term value catalysts, likely including clinical data readouts or partnership announcements within the next 12-18 months. This move carries elevated risk given IMNM's early-stage status but reflects Redmile's thesis on the commercial potential of its platform technology.